Abstract
Skeletal muscle is an attractive target for gene therapies to treat either local or systemic disorders, as well as for genetic vaccination. An ideal expression system for skeletal muscle would be characterized by high level, extended duration of expression and muscle specificity. Viral promoters, such as the cytomegalovirus (CMV) promoter, produce high levels of transgene expression, which last for only a few days at high levels. Moreover, many promoters lack muscle tissue specificity. A muscle-specific skeletal α-actin promoter (SkA) has shown tissue specificity but lower peak activity than that of the CMV promoter in vivo. It has been reported in vitro that serum response factor (SRF) can stimulate the transcriptional activity of some muscle-specific promoters. In this study, we show that co- expression of SRF in vivo is able to up-regulate SkA promoter-driven expression about 10-fold and CMV/SkA chimeric promoter activity by five-fold in both mouse gastrocnemius and tibialis muscle. In addition, co-expression of transactivator with the CMV/SkA chimeric promoter in muscle has produced significantly enhanced duration of expression compared with that shown by the CMV promoter-driven expression system. A dominant negative mutant of SRF, SRFpm, abrogated the enhancement to SkA promoter activity, confirming the specificity of the response. Since all the known muscle-specific promoters contain SRF binding sites, this strategy for enhanced expression may apply to other muscle-specific promoters in vivo.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Wolff JA et al. Direct gene transfer into mouse muscle in vivo Science 1990 247: 1465–1468
Wolff JA et al. Long-term duration of plasmid DNA and foreign gene expression in mouse muscle Hum Mol Genet 1992 1: 363–369
Danko I et al. Pharmacological enhancement of in vivo foreign gene expression in muscle Gene Therapy 1994 1: 114–121
Coney L et al. Facilitated DNA inoculation induces anti-HIV-1 immunity in vivo Vaccine 1994 12: 1545–1550
Aihara H, Miyazaki JI . Gene transfer into muscle by electroporation in vivo Nature Biotechnol 1998 16: 867–870
Mumper RJ et al. Protective interactive noncondensing (PINC) polymers for enhanced plasmid distribution and expression in rat skeletal muscle J Control Rel 1998 52: 191–203
Tripathy SK et al. Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector Proc Natl Acad Sci USA 1996 93: 10876–10880
Alila H et al. Expression of biologically active human insulin-like growth factor-I following intramuscular injection of a formulated plasmid in rats Hum Gene Ther 1997 8: 1785–1795
Anwer K et al. Systemic effect of human growth hormone after intramuscular injection of a single dose of a muscle-specific gene medicine Hum Gene Ther 1998 9: 659–670
Wells DJ, Goldspink G . Age and sex influence expression of plasmid DNA directly injected into mouse skeletal muscle FEBS Lett 1992 306: 203–205
Dai Y, Roman M, Naviaux RK, Verma IM . Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo Proc Natl Acad Sci USA 1992 89: 10892–10895
Chow KL, Schwartz RJ . A combination of closely associated positive and negative cis-acting promoter elements regulates transcription of the skeletal α-actin gene Mol Cell Biol 1990 10: 528–538
Petropoulos CP et al. The chicken skeletal muscle α-actin promoter is tissue specific in transgenic mice Mol Cell Biol 1989 9: 3785–3792
Barnhart KM et al. Enhancer and promoter chimeras in plasmids designed for intramuscular injection: a comparative in vivo and in vitro study Hum Gene Ther 1998 9: 2545–2553
Nettelbeck DM, Jerome V, Muller R . A strategy for enhancing the transcriptional activity of weak cell type-specific promoters Gene Therapy 1998 5: 1656–1664
Lee TC, Chow KL, Fang P, Schwartz RJ . Activation of skeletal α-actin gene transcription: the cooperative formation of serum response factor-binding complexes over positive cis-acting promoter serum response elements displaces a negative-acting nuclear factor enriched in replicating myoblasts and nonmyogenic cells Mol Cell Biol 1991 11: 5090–5100
Chen CY, Schwartz RJ . Competition between negative acting YY1 versus positive acting serum response factor and tinman homologue Nkx-2.5 regulates cardiac α-actin promoter activity Mol Endocrinol 1997 11: 812–821
Walsh K . Cross-binding of factors to functionally different promoter elements in the c-fos and skeletal actin genes Mol Cell Biol 1989 9: 2191–2201
Croissant JD et al. Avian serum response factor expression restricted primarily to muscle cell lineages is required for α-actin gene transcription Dev Biol 1996 177: 250–264
Gius D et al. Transcriptional activation and repression by Fos are independent functions: the C terminus represses immediate–early gene expression via CarG elements Mol Cell Biol 1990 10: 4243–4255
Miwa T et al. Structure, chromosome location and expression of the human smooth muscle (enteric type) gamma-actin gene: evolution of six human actin genes Mol Cell Biol 1991 11: 3296–3306
Gilman MZ, Wilson RN, Weinerg RA . Multiple protein-binding sites in the 5′-flanking region regulate c-fos expression Mol Cell Biol 1986 6: 4305–4316
Lee TC, Shi Y, Schwartz RJ . Displacement of BrdUrd-induced YY1 by serum response factor activates skeletal α-actin transcription in embryonic myoblasts Proc Natl Acad Sci USA 1992 89: 9814–9818
Chen CY et al. Activation of the cardiac α-actin promoter depends upon serum response elements Dev Genet 1996 19: 119–130
Gauthier-Rouviere C et al. Expression and activity of serum response factor are required for muscle determining factor MyoD in both dividing and differentiating mouse C2C12 myoblasts Mol Biol Cell 1996 7: 719–727
Belaguli N, Schildmeyer L, Schwartz RJ . Organization and myogenic restricted expression of the murine serum response factor gene J Biol Chem 1997 272: 18222–18231
Martin KA et al. A competitive mechanism of CarG element regulation by YY1 and SRF: implications for assessment of Phox1/Mhox transcription factor interactions at CarG elements DNA Cell Biol 1997 16: 653–661
Gualberto A et al. Functional antagonism between YY1 and the serum response factor Mol Cell Biol 1992 12: 4209–4212
Coleman ME et al. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice J Biol Chem 1995 270: 12109–12116
Acknowledgements
We thank Dr Ron Brywes’s laboratory for some of SRF constructs and Alain Rolland, Mike Fons and Sean Sullivan for their critical reading of the manuscript.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Li, S., MacLaughlin, F., Fewell, J. et al. Increased level and duration of expression in muscle by co-expression of a transactivator using plasmid systems. Gene Ther 6, 2005–2011 (1999). https://doi.org/10.1038/sj.gt.3301032
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301032
Keywords
This article is cited by
-
In Vivo Anti-Tumor Effect of Expressing p14ARF-TAT Using a FGF2-Targeted Cationic Lipid Vector
Pharmaceutical Research (2011)
-
Development of Peptide-targeted Lipoplexes to CXCR4-expressing Rat Glioma Cells and Rat Proliferating Endothelial Cells
Molecular Therapy (2008)
-
Preferential expression of hPGFS in primary SCCHN and tumour cell lines derived from respiratory and digestive organs
British Journal of Cancer (2004)
-
Non-viral gene delivery in skeletal muscle: a protein factory
Gene Therapy (2003)
-
Regression of tumors by IFN-α electroporation gene therapy and analysis of the responsible genes by cDNA array
Gene Therapy (2002)